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Abstract: The homing of Endothelial Progenitor Cells (EPCs) to tumor angiogenic sites has been
described as a multistep process, involving adhesion, migration, incorporation and sprouting,
for which the underlying molecular and cellular mechanisms are yet to be fully defined.
Here, we studied the expression of Junctional Adhesion Molecule-C (JAM-C) by EPCs and its
role in EPC homing to tumor angiogenic vessels. For this, we used mouse embryonic-Endothelial
Progenitor Cells (e-EPCs), intravital multi-fluorescence microscopy techniques and the dorsal skin-fold
chamber model. JAM-C was found to be expressed by e-EPCs and endothelial cells. Blocking JAM-C
did not affect adhesion of e-EPCs to endothelial monolayers in vitro but, interestingly, it did reduce
their adhesion to tumor endothelium in vivo. The most striking effect of JAM-C blocking was on tube
formation on matrigel in vitro and the incorporation and sprouting of e-EPCs to tumor endothelium
in vivo. Our results demonstrate that JAM-C mediates e-EPC recruitment to tumor angiogenic sites,
i.e., coordinated homing of EPCs to the perivascular niche, where they cluster and interact with tumor
blood vessels. This suggests that JAM-C plays a critical role in the process of vascular assembly and
may represent a potential therapeutic target to control tumor angiogenesis.
Keywords: JAM-C; endothelial progenitors; adhesion; migration; tumor angiogenesis; perivascular niche
1. Introduction
Over the last two decades, it became clear that tumor vascularization occurs through two distinct
but complementary processes, namely, neoangiogenesis (the sprouting and remodeling of pre-existing
blood vessels) and vasculogenesis (the de novo formation of blood vessels through the mobilization and
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recruitment of Endothelial Progenitor Cells (EPCs) into the developing vasculature) [1,2]. Since the first
identification of EPCs in adults [3], a substantial number of studies reported an active role of EPCs in
postnatal neovascularization [4–8]. However, the relative contribution of EPCs to adult neovasculature
is highly debated and has been controversially reported to range from minor [9,10] to relatively high [11].
Using mouse embryonic-Endothelial Progenitor Cells (e-EPCs) [7], we previously demonstrated that
their recruitment during tumor angiogenesis in vivo is a multistep process that requires a coordinated
sequence of events, similar to leukocyte recruitment to inflammatory tissues [8]. The process comprises
the activation of the tumor endothelium, arrest and firm adhesion to the endothelium, transendothelial
extravasation into the interstitial space, perivascular formation of cellular clusters and finally interaction
of e-EPCs with the angiogenic tumor vasculature [8]. In particular, we demonstrated that E- and
P-selectin expressed on tumor endothelium exclusively mediate the initial e-EPC arrest at tumor
angiogenic sites [8]. Similar findings were recapitulated using human cord blood-derived EPCs [12].
Members of the Junctional Adhesion Molecule family (JAMs) have been implicated in leukocyte
transendothelial migration [13–15] and angiogenesis [16]. JAM-A, JAM-B and JAM-C, the three
classical members of the JAM family, are characterized by an extracellular region with two
immunoglobulin-like domains, a single transmembrane domain and a short cytoplasmic tail
with a PDZ-domain-binding motif [17,18]. JAM-C is expressed at vascular cell–cell contacts [19]
and was also identified on circulating human platelets, natural killer cells, dendritic cells, B
lymphocytes and a subset of T lymphocytes, but not on circulating mouse leukocytes [20–22].
Although JAM-C was detected in epithelial cell desmosomes [23], its association with the PDZ
proteins ZO-1 and PAR3 suggests a preferential localization in endothelial cell tight junctions [19,24].
JAM-C, like the other members of the JAM family, has been described as potentially capable of
forming homophilic (endothelial JAM-C/endothelial JAM-B, endothelial JAM-B/leukocyte JAM-C,
endothelial JAM-C/leukocyte ß2 integrins or platelets JAM-C/leukocytes JAM-C) and heterophilic
interactions (endothelial JAM-C/endothelial JAM-B, endothelial JAM-B/leukocyte JAM-C, endothelial
JAM-C/leukocyte ß2 integrins or platelet JAM-C/leukocyte JAM-C) [17,25,26].
In particular, we and others demonstrated that JAM-C is involved in leukocyte recruitment by
mediating transendothelial and reverse transmigration [13,25,27,28]. Moreover, JAM-C was also shown
to be involved in angiogenesis and tumor growth [16,29–31].
However, to date, no study has investigated the potential role of JAM-C in EPC recruitment during
tumor angiogenesis. In this work, we decided to use e-EPCs as a model of endothelial progenitor cells.
These cells are well-characterized [32] and represent a more robust model compared to EPCs derived
from umbilical cord, for example, which may be subject to higher variability batch-to-batch as a result
of differing umbilical cord blood preparations.
We hypothesized that JAM-C, expressed by the tumor endothelium, is responsible for transvascular
migration of e-EPCs. In this study, by using noninvasive in vivo multi-fluorescence microscopy
techniques, as well as in vitro functional assays mimicking the different steps of EPC recruitment,
we addressed this question.
2. Results
2.1. JAM-C is Expressed by e-EPCs and Localizes at Tight Junctions
As JAM-C is expressed by hemopoietic stem cells and vascular endothelium [33] we hypothesized
that JAM-C may also play a role in the recruitment of endothelial progenitor cells at sites of tumor
angiogenesis. To address this question, we used mouse embryonic-Endothelial Progenitor Cells
(e-EPCs) as a model and analyzed their JAM-C expression. JAM-C mRNA was expressed by e-EPCs,
although at slightly lower levels than the H5V endothelial cell line used as positive control (Figure 1A).
Confocal microscopy images showed that e-EPCs and H5V cells express JAM-C protein at sites of
cell–cell contact (Figure 1B: a, c, g, i). Double staining of JAM-C and ZO-1 showed co-localization of the
two proteins at the tight junctions in e-EPC as well as in H5V cells (Figure 1B: b, c, h, i). Images acquired
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on the z-axis of the cell monolayer confirmed protein localization of JAM-C at the cell junctional regions
(Figure 1B: d, e, f, j, k, l).
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Figure 1. Junctional Adhesion Molecule-C (JAM-C) expression and localization in endothelial cells
and embryonal-Endothelial Progenitor Cells (e-EPCs). (A) RT-PCR of JAM-C in e-EPCs and in the
mouse end thelial H5V cell line (used as positive control). The results shown are representative of
3 independe t experiments. GAPDH was used as an internal control. (B) Representative images of
H5V and e-EPC monolayers showing JAM-C (a, g) and ZO-1 (b, h) expression and distribution at
inter-endothelial contacts. Images were merged to analyze the co-localization of JAM-C with ZO-1
(c, i). Images on the z-axis confirmed the co-localization of JAM-C with ZO-1 at tight junctions (d, e, f, j,
k, l). Images were acquired using a confocal microscope (Leica TCPSP2 Leica, Bensheim Germany).
To test whether e-EPCs and endothelial cells interacted in a homophilic or heterophilic
manner [26,34], the expression of JAM-B, a reported counter-receptor of JAM-C, was investigated.
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Using RT-PCR, we found that JAM-A, but not JAM-B, was expressed by the e-EPCs (Supplementary
file 1A). Moreover, we found via FACS analysis that the e-EPCs also did not express β2-integrin,
another described receptor of JAM-C (Supplementary file 1B). Thus, based on these findings, we
concluded that e-EPCs interact via JAM-C in a homophilic way in trans-orientation.
2.2. Role of JAM-C on e-EPC Adhesion and Transendothelial Migration In Vitro
To investigate whether JAM-C mediates e-EPC adhesion to endothelial cells and/or transendothelial
migration, we used the anti-JAM-C blocking antibody H33 [30].
For adhesion, e-EPCs were allowed to adhere for 20 min on top of confluent endothelial cell
(H5V and human umbilical vein endothelial cell (HUVEC)) monolayers in the absence or presence of
the anti-JAM-C antibody. The antibody against JAM-C did not affect e-EPC adhesion (Figure 2A).
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Figure 2. Blocking JAM-C via monoclonal antibody: Effect on e-EPC adhesion and transendothelial
migration in vitro. (A) Adhesion: Human umbilical vein endothelial cell (HUVEC) monolayers were
preincubated in the absence (untreated) or in the presence of H33 anti-JAM-C monoclonal antibody.
The fluorescence of cell-tracker green-labeled adherent cells was measured. Data are represented by mean
± SD (n = 3). (B) Transendothelial migration: A transwell system was used. HUVEC monolayers and
e-EPCs were in the absence (untreated) or presence of anti-JAM-C antibody H33. e-EPCs were then plated
in the upper chamber onto the HUVEC monolayer to transmigrate in response to tumor-conditioned
medium (TCM) or not (unstimulated). Transmigrated cells were stained with DAPI and counted using a
fluorescence microscope. Data are represented by mean ± SD (n = 3); ** p < 0.01.
Based on the strong tumor tropism of e-EPCs in vitro (Supplementary file 2) and in vivo [8],
we tested whether JAM-C would be involved in the process of transendothelial migration in response
to tumor-conditioned medium. Blockage with H33 anti-JAM-C antibody significantly reduced e-EPC
transmigration (Figure 2B).
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2.3. Inhibition of JAM-C Reduces the Formation of Cord-Like Structures on MatrigelTM In Vitro
During the complex process of EPC recruitment to tumor blood vessels, important steps include
integration into the vascular network and angiogenic sprouting. We have already shown that human
adult EPCs are able to be incorporated into the vascular network, both in vitro and in vivo [12,35]. Here,
we aimed to understand whether JAM-C contributed to the process. As we previously found, e-EPCs
by themselves did not form cord-like structures, but they were able to do so upon treatment with c-AMP,
referred to as embryonic-Endothelial Progenitor-Derived Cells (e-EPDCs) [35]. Thus, we performed
tube formation assays using e-EPDCs and HUVECs (Figure 3). Inhibition of JAM-C with either
anti-JAM-C monoclonal antibody H33 or the soluble recombinant JAM-C (human for HUVECs and
mouse for e-EPDCs), significantly reduced the formation of the cord-like structure,= by HUVECs and
e-EPDCs (Figure 3A–C; 3B *** p < 0.001 and 3C ** p < 0.01).
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Figure 3. Blocking JAM-C via monoclonal antibody reduces in vitro cord-like structures on
MatrigelTM. (A) Representative images of HUVEC cord-like structures and embryonic-Endothelial
Progenitor-Derived Cells (e-EPDCs) cultured on matrigel for 24 h, untreated, treated with anti-JAM-C
antibody H33 or with recombinant (r-JAM-C) human JAM-C or mouse JAM-C are shown. (B-C) Total
tube length was reported for HUVEC (B) and the total area of cord-structures for e-EPDCs (C). Data are
represented by mean ± SD f three separate experiments (** p < 0.01, *** p < 0.001, compared to control
values). Scal bar is 50 µm.
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2.4. Knockdown of JAM-C Reduces in Vitro Cord-Like Structures on MatrigelTM
To further confirm the function of JAM-C during angiogenesis, we used an siRNA approach to
directly silence human JAM-C in HUVECs and mouse JAM-C in e-EPCs. Transfection efficiency was
tested using control siRNA coupled to Alexa Fluor 488, while MAPK-1 siRNA served as the positive
control. Real-time PCR showed that JAM-C siRNA strongly decreased mRNA expression levels of
JAM-C in HUVECs and e-EPCs (Figure 4A,C). To check the silencing at the protein level, cells were
harvested 72 h after siRNA transfection and JAM-C was immunoprecipitated. Blots showed a strong
decrease in JAM-C protein levels with siRNA-treated HUVECs and e-EPCs compared to controls
(Figure 4B,C). The JAM-C-silenced cells (HUVECs and e-EPDCs) were then used for the in vitro
angiogenesis assay on MatrigelTM. Twenty-four hours after seeding, both siRNA-transfected cell types
clearly showed thinner tubes compared to control cells (Figure 4E,G). After 48 h, both untransfected
and control siRNA cells maintained their cord-like structures, while the tubes almost completely
disappeared in the JAM-C siRNA-treated cells. JAM-C-silenced HUVECs and e-EPDCs frequently
tended to lose cell–cell contact and remained as single cells. Quantification of total tube length at 24 h
and 48 h confirmed a significant decrease in tube formation in both JAM-C siRNA-silenced cell types
(Figure 4F, *** p < 0.001 and 4H, *** p < 0.001, ** p < 0.01).
2.5. Role of JAM-C on e-EPC Adhesion and Extravasation In Vivo
Our in vitro data suggest that JAM-C mediates recruitment of e-EPCs to the perivascular niche.
To investigate the role of JAM-C during e-EPC recruitment to sites of tumor angiogenesis in vivo,
we used the syngeneic Lewis-Lung-Carcinoma (LLC) tumor model in the dorsal skin-fold chamber.
Between 14 and 17 days after tumor cell implantation, intravital microscopy was performed to visualize
the LLC tumor microvasculature. This showed the typical angio-architecture of the LLC tumor model
characterized by high angiogenic activity (Supplementary file 3A). JAM-C expression by LLC tumor
vessels was examined by fluorescent immunostaining. Co-staining with the endothelial cell marker
PECAM-1 (Supplementary file 3B) revealed endothelial-specific staining for JAM-C on LLC tumor
vessels, while tumor cells were negative for JAM-C.
Mice bearing LLC tumors were injected with anti-JAM-C H33 or an IgG control antibody.
After 20 min, DiI pre-labeled e-EPCs were injected into mice and e-EPC/tumor vessel interactions
were analyzed by intravital multi-fluorescence video-microscopy at different time points after e-EPC
injection: At time 0, the first interaction was established; 5 min post-injection, firm adhesion was
established; at 1 h, extravasation was established; and finally at 2 days post-cell injection, e-EPC
incorporation into blood vessels was determined. As previously shown, immediately after cell injection,
the circulating e-EPCs homed to the tumor vessel endothelium [8]. At this stage, cells either tethered or
adhered to the tumor blood vessel wall. We observed that the e-EPCs injected into H33 pre-treated mice
showed a similar initial e-EPC/tumor blood vessel interaction compared to control mice (Figure 5A).
However, 5 min after cell injection, a significantly lower number of firm adherent e-EPCs to the tumor
blood vessel was found in the H33 treated mice versus the IgG control (Figure 5B).
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Figure 4. Knockdown of JAM-C reduced in vitro cord-like structures on atrigelTM. (A) The mRNA
expression levels of human JAM-C in HUVECs transfected with siRNA against JAM-C or with control
siRNA isolated at 24, 48 and 72 h after transfection. The 48 h time point showed the strongest
knockdown of JAM-C m-RNA levels. Data are represent d by mean ± SD (n = 3). (B) The protein
expression level of human JAM-C was anal zed by Western blot in HUVECs transfected with siRNA
against JAM-C or with control siRNA, showing a strong decrease in total cellular JAM-C protein levels.
Cell surface biotinylation, lysis and JAM-C precipitation were performed 72 h after transfection. Cell
lysates from HUVECs transfected with control siRNA or JAM-C siRNA were probed with anti-human
JAM-C polyclonal antibody. Equivalent amounts of protein were loaded. As an internal control,
anti-human JAM-C was loaded alone. (C) The mRNA expression levels of mouse JAM-C showed that
JAM-C siRNA treatment decreased JAM-C mRNA levels. (D) The protein expression levels of mouse
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JAM-C showed a strong decrease in total cellular JAM-C protein levels. (E) Representative images of
cord-like structures from HUVECs untransfected or transfected with control siRNA or with JAM-C
siRNA, after 24 h and 48 h on matrigel, are shown. (F) Quantitative evaluation of HUVEC cord-like
structures, was performed by determining the total tube length. Data are represented by mean ±
SD of a representative experiment (*** p < 0.001 compared to the untransfected levels and to control
siRNA levels, n = 12). (G) Representative images of cord-like structures from e-EPDC untransfected
or transfected with control siRNA or with JAM-C siRNA, after 24 h and 48 h on matrigel, are shown.
(H) Quantitative evaluation of e-EPDC cord-like structures determining the total area of cord structure.
Knockdown of JAM-C significantly reduced the cord-like structure when e-EPDCs were transfected
with JAM-C siRNA. Data are represented by mean ± SD of a representative experiment; similar results
were observed in separate experiments, with each one performed in triplicate (** p < 0.01, *** p < 0.001
compared to untransfected levels and to control siRNA levels, n = 12). Scale bar is 50 µm.
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clusters in proximity to tumor vascular sprouts [8]. Interestingly, we found that H33-treated mice 
revealed significantly fewer elongated, clustered cells localized to the perivascular niche compared 
to the IgG-treated control mice (Figure 6A; ** p < 0.01 vs. IgG; IgG: n = 14, H33: n = 16). The 
representative intravital video-microscopic images shown in Figure 6B demonstrate how 
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Figure 5. Blocking JAM-C via monoclonal antibody: Effect of e-EPC homing to tumor angiogenesis
in vivo. C57BL/6 mice bearing LLC tumors in dorsal skin-fold chambers were pre-injected with Isotype
control antibody 9B5 (n = 2) or anti JAM-C H33 (n = 4). After 20 min, DiI pre-labeled e-EPCs were
intra-arterially injected into each group of mice and their recruitment to the tumor microvessels
was analyzed by epi-fluorescent intravit l vide -microscopy. Mic oscopy and video analysis of cell
interactions were performed at different time points: t0 = injection/first interaction (A); t1 = 5 min/firm
adhesion (B); t2 = 1 h/extravasation (C), t3 = 2 days/long term recruitment (D), showing that JAM-C
significantly reduced e-EPCs during firm adhesion and the incorporation steps of e-EPC homing. Data
are represented by mean ± SD (* p < 0.05, ** p < 0.01, compared to IgG control).
We previously showed that, within 1 h after cell injection, arrested e-EPCs started to extravasate
into the tumor [8]. Thus, we checked e-EPC extravasation 1 h after cell injection and found the number
of transmigrated cells was reduced in H33 mice versus IgG mice, alt ough this was not significant
(Figure 5C).
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2.6. Anti-JAM-C H33 Monoclonal Antibody Reduces the Recruitment of e-EPCs into the Perivascular Niche
and Leads to Loss of e-EPCs in the Tumor Interstitium
Next, we studied the integration of e-EPCs into the perivascular tissue. Mice were intraperitoneally
(IP) injected daily with H33 anti-JAM-C antibody or control IgG antibody. On day 2 after cell injection,
intravital multi-fluorescent video-microscopy was performed and showed a significantly lower number
of incorporated e-EPCs in H33 treated mice compared to IgG control mice (Figure 5D). Within a few
days after integration, extravasated e-EPCs started to elongate and form clusters in proximity to
tumor vascular sprouts [8]. Interestingly, we found that H33-treated mice revealed significantly fewer
elongated, clustered cells localized to the perivascular niche compared to the IgG-treated control mice
(Figure 6A; ** p < 0.01 vs. IgG; IgG: n = 14, H33: n = 16). The representative intravital video-microscopic
images shown in Figure 6B demonstrate how extravasated e-EPCs in the control group were recruited
to the perivascular niche, where they clustered and interacted with tumor blood vessels and displayed
a clear elongated shape. In contrast, in the H33-treated group, extravasated cells failed to localize to
the perivascular niche, retained a rounded shape and did not interact with sprouting tumor blood
vessels. They were virtually lost into the interstitial space.
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elongated and polarized shapes. Morphological changes were significantly reduced in the a ti-JAM-C
H33 group compared with the isotype control antibody 9B5 treated group. Data are represented by
mean ± SD (*** p < 0.01 H33 vs. IgG; IgG: n = 14, H33: n = 16). (B) Representative images of recruited
e-EPC for each group (IgG, H33) on day 2 after cell injection. Tumor microvasculature after contrast
enhancement by FITC-dextran (Fluorescein isothiocyanate-dextran) (a, d); DiI-labeled e-EPCs in the
same regions of interest (b, e); merged images (c, f) showing e-EPCs characterized mostly by a rounded
shape in the H33 group, in comparison with cells recruited in the control IgG-treated mice, which were
characterized by an elongated shape.
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3. Discussion
Several studies identified JAM-C as one of the molecules involved in the multistep process of
leukocyte recruitment to inflammatory tissues, in particular during the transmigration process [20,23,25,28].
The recruitment of Endothelial Progenitor Cells (EPCs) to sites of tumor angiogenesis is also a multistep
process, and although JAM-C was demonstrated in several studies to play a role in angiogenesis and
tumor growth [18,30,31,36], none of the studies addressed the role of JAM-C in the context of endothelial
progenitor cell recruitment to tumor angiogenesis. To address this question, we first investigated JAM-C
expression on EPCs, endothelial cells and tumors. Then, we studied the potential function of JAM-C
during the different steps of EPC recruitment to tumor angiogenesis.
Relative to JAM-C expression, JAM-C has been described to be localized at various cell–cell
contacts, including vascular endothelial tight junctions [19,37,38] and epithelial desmosomes [23]
and also human leukocytes, platelets and polarized spermatids [39]. In line with what was partly
reported in previous studies, we found that JAM-C is expressed by endothelial cells and EPCs, and
that it co-localizes with the tight junction marker ZO-1. In vivo, we detected JAM-C on tumor blood
vessel endothelia (in the LLC1 tumor model), but not on the tumor cells themselves. JAM-C can also
engage in homophilic or heterophilic interactions [17,25,26]. We found that e-EPCs express JAM-A
but not JAM-B (the JAM-C ligand), and e-EPCs do not express the protein members of the ß2-integrin
family such as LFA-1 and MAC-1, the latter of which was reported to be a leukocyte JAM-C counter
receptor [28]. This suggested that the interaction between e-EPCs and endothelial cells is mediated by
JAM-C/JAM-C homophilic interactions.
To investigate at which step JAM-C is involved in EPC recruitment to develop tumor vasculature,
we used a specific monoclonal antibody against JAM-C (H33) that was previously proven to inhibit
angiogenesis and tumor growth [30].
In vitro, blocking of JAM-C via H33 slightly affected e-EPC adhesion to and transmigration through
endothelial monolayers. Remarkably, H33 more efficiently reduced the formation of cord-like structures.
The effect on tube formation was further supported by the use of two additional/complimentary
approaches to inhibit JAM-C function, namely, the addition of soluble, recombinant JAM-C protein
or JAM-C knockdown with siRNA. We showed that in the absence of JAM-C, blockade of JAM-C
or competition by the soluble molecule, both endothelial cells and e-EPDCs were unable to align
and connect into a vascular network during the in vitro surrogate angiogenesis assay. These results
were important, since they identified JAM-C as a key player in the cascade of e-EPC recruitment to
angiogenic sites in tumors and, more specifically, suggested that JAM-C was required for endothelial
progenitor cells and mature endothelial cells to form cell–cell contacts, cell clusters and subsequent
elongation into a vascular network. To better understand these unexpected findings, in vivo studies
were performed to monitor e-EPC recruitment under physiological conditions of tumor angiogenesis.
By using the LLC1 tumor model in the dorsal skin-fold chamber, we looked at the recruitment of
e-EPCs to tumor angiogenesis and, by interfering with JAM-C function via H33 monoclonal antibody,
we observed effects on multiple steps, including firm adhesion, incorporation and sprouting. For the
firm adhesion, the results obtained in vivo were in contrast with those obtained in vitro. This could be
explained by the presence in vivo of blood shear stress by flow, which itself strongly affects the e-EPC
interactions with blood vascular endothelia, both in vitro and in vivo [12].
Our previous in vivo studies showed that extravasated e-EPCs form clusters and localize in
proximity to tumor vascular sprouts within the perivascular niche. After a few days, e-EPCs begin to
elongate and eventually interact with tumor endothelium [8]. In this study, we found that blocking
JAM-C prevented perivascular incorporation of extravasated e-EPCs, as well as their clustering and
interactions with tumor blood vessels. Upon blocking of JAM-C, extravasated cells to the interstitial
space remained rounded, isolated and passive. This suggested that JAM-C are needed for e-EPC
recruitment to the perivascular niche and interactions with the adjacent tumor endothelium, a critical
step in the process of vascular assembly and tumor angiogenesis. These in vivo data are indeed in line
with our in vitro results.
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Our data are also in line with previous studies that presented evidences for a role of JAM family
members in angiogenesis [30,40,41]. Of particular relevance is a study that demonstrated a complete
loss of lumen and tube formation by mature endothelial cells after blockage of both JAM-B and JAM-C
using antibodies, siRNA or dominant negative mutants [40]. However, blocking of JAM-C in EPCs
should be carefully considered, as this could have effects in other contexts too, such as physiological
processes like during endometrial regrowth, or other pathophysiological processes like cardiac and
retinal ischemia.
Although it is widely accepted that EPCs are involved in the process of tumor angiogenesis,
their direct contribution to the composition of new blood vessels is still a matter of debate [5,6,8,11,42–44].
We provided evidence for the role of JAM-C as a principal actor of EPC participation in tumor
angiogenesis. The recruitment of EPCs to the perivascular niche requires the elongation of cells,
alignment of adjacent cells and rearrangement of cell–cell contacts. We propose that JAM-C plays
a key role in this scenario and our hypothesis is supported by several pieces of evidence that
identified JAM-C as a critical molecule in the organization of the tight junctional and cell polarity
complexes [24,38,39,45,46]. Of particular relevance is the recent study that showed JAM-C to be a
critical molecule for the differentiation of round spermatids into polarized spermatocytes [39].
In conclusion, we suggest that JAM-C is a potential therapeutic target to control tumor angiogenesis,
since an antibody-based approach could inhibit the angiogenic functions of both mature endothelial
cells and, in particular, as shown here, endothelial progenitors.
4. Materials and Methods
4.1. Cells and Cell Culture
Human umbilical vein endothelial cells (HUVECs) were used for the in vitro studies.
Umbilical cords were obtained from normal pregnancies immediately after delivery [12]. HUVECs
were isolated by trypsin treatment of umbilical cord veins and used at passages 1–6. Cells were grown
in culture flasks precoated with 0.5% gelatin (Sigma-Aldrich, Steinheim, Germany) at 37 ◦C in 5% CO2
and cultured in Endothelial Cell Growth Medium (Promocell, Heidelberg, Germany).
The murine immortalized endothelial cell line H5V (a kind gift from Prof. Elisabetta Dejana, IFOM,
Milano, Italy) and the murine Lewis Lung Carcinoma cell line (LLC1), were grown in high-glucose
Dulbecco’s modified Eagles medium supplemented with 2 mM L-glutamine, 1× Na pyruvate, 1×
penicillin/streptomycin and 10% Fetal calf serum (FCS) (Sigma-Aldrich, Hamburg, Germany) at 37 ◦C
in 5% CO2. The SF188 human glioma cell line was grown in low-glucose Dulbecco’s modified Eagles
medium supplemented with 2 mM L-glutamine, 1X Penicillin/Streptomycin and 10% FCS (all from
Sigma-Aldrich, Hamburg, Germany).
Isolation and culture of mouse embryonic-Endothelial Progenitor Cells (e-EPCs) and embryonic-
Endothelial Progenitor-Derived Cells (e-EPDCs; obtained upon differentiation with cAMP and retinoic
acid) were as previously described [8,32].
To derive tumor-conditioned medium (TCM), SF188 cells were harvested and 1.5 x 106 cells were
plated in 75 cm2 tissue culture flasks in their specific culture conditions for 4 days. Eighteen hours
before collecting the medium, a serum starvation was performed. The medium was removed from
the tissue culture flask, the cell monolayers were washed twice with basic Migration Assay Medium
(MAM) (serum and protein free DMEM, 25 mM HEPES, 1X penicillin, 1X streptomycin and 2 mM
L-glutamine) and 10 mL of warm MAM medium (0.5% Bovine Serum Albumine (BSA) in MAM
medium) was added to the cells. After 18 h of serum starvation, the supernatant was collected from the
tissue culture flask, centrifuged at 1800 rpm for 10 min and passed through a 0.22 µm filter. Aliquots
were stored at –80 ◦C.
For the in vivo experiments, adherent e-EPCs were fluorescently labeled with the lipid soluble dye
DiI (1,1’-dioctadecyl-3,3,3’,3’-tetramethylindo-carbacyanine perchlorate) at 30 µg/mL in normal culture
medium for 4 h at 37 ◦C. Cells were washed twice with PBS 1× and after detachment with trypsin,
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centrifuged and washed three times with Phosphate buffer saline (PBS) 1×. The cells were resuspended
in normal culture medium, filtered through a 40 µm cell strainer and counted. Immediately prior to
injection, the cells were centrifuged again and resuspended in 0.9% NaCl.
4.2. Immunofluorescence Staining
For immunocytochemistry, cell monolayers were fixed for 5 min with ice-cold methanol, washed
in PBS containing 0.1% BSA (Sigma-Aldrich, Steinheim, Germany) and blocked with 2% BSA in PBS for
45 min. Cells were double stained for JAM-C and ZOI-1 by incubation for 2 h at room temperature with
polyclonal goat anti-mouse JAM-C (R&D, Wiesbaden, Germany) followed by biotinylated anti-goat IgG
(Vector Laboratories, Wertheim-Bettingen, Germany), cy2-streptavidin-conjugated antibody (Jackson
Immunoresearch Laboratories) and ZO-1 with rabbit anti-mouse ZO-1 (Zymed Lab, San Francisco,
CA, USA), followed by goat anti-rabbit IgG cy3-conjugated (Jackson Immunoresearch laboratories).
Images were acquired using a confocal microscope (Leica TCPSP2 Leica, Bensheim Germany).
For immunohistochemistry, 10 µm frozen sections of LLC1 tumor explanted from the dorsal skin
fold chamber (n = 3; 17 days after the implantation) were fixed for 5 min with ice-cold methanol and
dried and rehydrated in PBS, 0.2% gelatin and 0.05% Tween 20 (PGT). Sections were triple stained
for 2 h at room temperature for PECAM-1 (Platelet Endothelial Cell Adhesion Molecule-1) as the
internal control, with rat monoclonal anti-mouse PECAM-1 (BD, Pharmingen, San Diego, CA, USA),
followed by cy3-conjugated anti-rat IgG (Chemicon, Temecula, CA USA), and for JAM-C by incubation
with rabbit polyclonal anti-mouse JAM-C followed by FITC-conjugated anti-rabbit IgG (ICN Aurora
OH USA) and nuclei stained by DAPI in the mounting medium. Images were acquired using a
fluorescent microscope (Axioplan 2 imaging, Zeiss, Jena, Germany) with 400×magnification.
4.3. siRNA and Transfection
For transfections, the following reagents and chemically synthesized siRNAs were used: HiPerfect
Transfection reagent, a nonsilencing control Alexa Fluor 488 labeled siRNA (to check transfection
efficiency), an All Stars negative control siRNA, a positive control siRNA Mn/Hs _MAPK-1, two siRNAs
against human JAM-C: Hs_JAM-3_1 HP siRNA, Hs_JAM3_5 HP siRNA and two siRNAs directed
against murine JAM-C: Mm_JAM3_1 HP siRNA, Mm_JAM3_4 HP siRNA (all from Qiagen, Hilden,
Germany). Combinations of two different siRNAs were transfected at a concentration of 5 nM to
produce JAM-C silencing in HUVECs and e-EPDCs. For transfections, e-EPDCs were grown in
appropriate culture medium + 10% FCS. In both cases, cells were used in the experiments 72 h after
transfection, as described below.
4.4. RT-PCR and Analysis
Reverse transcription polymerase chain reaction (RT-PCR) was used to evaluate the expression of
JAM-C mRNA in e-EPCs and H5V endothelial cells, which was used as a positive control. Total RNA
was isolated from cells using the Genelute Mammalian Total RNA Kit (Sigma-Aldrich, Steinheim,
Germany) and subjected to reverse transcription using poly-dT-Primers and M-MLVRT (Moloney
Murine Leukemia Virus Reverse Transcriptase)(-H) (Promega, Mannheim, Germany). Single-stranded
cDNA was used for PCR amplification according to standard protocols. The primer sequences were as
follows (Target, Sequence 5′–3′, Annealing Temperature (◦C), MgCl2): mouse JAM-C fw: TCG ACA
TGG CGC TGA GC, rv: CAG TGT TGC CGT CTT GCC TAC AG, 55 ◦C, 1.5mM; mouse JAM-A fw:
GTA ACT GTA ATG GGC ACC GAG, rv: CAC AGC ATC CAT GTG TGC AGC CTC, 62 ◦C, 2.5mM;
mouse JAM-B fw: CCT GGA CTA TCA TAA GGC AAA TGG, rv: CAT CTT TAA ACC AGA TGT ACT
CCG GA, 62 ◦C, 2.5 mM (RT-PCR for JAM-A and JAM-B, as shown in Supplementary file 1). Control
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) amplification was performed under the same
conditions as JAM-C PCR and the following primer sequences were used: mouse GAPDH fw: CTC
ACT CAA GAT TGT CAG CAA TG, rv: GAG GGA GAT GCT CAG TGT TGG. The PCR products were
460 base pairs (bp) for JAM-C and 668 bp for GAPDH.
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Quantitative real-time RT-PCR (qRT-PCR) was performed with the sequence detection system
ABI Prism 7700 (Applied Biosystems) using 2× ABgene Master Mix (ABgene, Epson, UK) and the
following gene expression assays: h-JAM-C: Hs00230289_m1; m-JAM-C: Mm00499214_m1; h-GAPDH:
Hs02758991_g1; m-GAPDH: Mm99999915_g1. GAPDH was used as a housekeeping gene. All reagents
were purchased from Applied Biosystems, Darmstadt, Germany.
Levels of gene expression were determined by the comparative CT (threshold cycle) method
(DDCT). The relative JAM-C expression was presented as arbitrary units of the ratio of CT of JAM-C
over CT of GAPDH.
4.5. Cell-Surface Biotinylation/JAM-C Immunoprecipitation
Cell-surface biotinylation was performed with some modifications compared to previously
described methods [19,22,28]. HUVEC and e-EPC monolayers were washed three times following
incubation with 2 mM NHS-PEO4-biotin (Pierce–Southfield, MI, USA) for 30 min at room temperature.
Cell lysates were obtained using 1% Np-40, 50 mM Tris pH 8 and 150 mM NaCl, including protease
inhibitors. Approximately 1 µL of rabbit polyclonal anti-human or anti-mouse JAM-C was added to
300 µg HUVEC cell lysate or 250 µg e-EPC cell lysate, respectively, and incubated at 4 ◦C overnight.
Biotinylated JAM-C proteins were precipitated with protein A-Sepharose (Pierce, Rockford, IL, USA),
boiled for 10 min in SDS sample buffer and separated using 10% SDS gels. Following transfer to
polyvinylidene difluoride membrane, biotinylated proteins were detected using avidin-horseradish
peroxidase (1:2000) and enhanced chemiluminescence (Lumiphos WB, Pierce, USA).
4.6. In Vitro Cell–Cell Adhesion Assay
The cellular adhesion assay was performed in 96-well plates (Greiner Bio-one) previously coated
with 10 µg/mL fibronectin (Sigma-Aldrich, Steinheim, Germany). Confluent HUVEC monolayers were
preincubated for 20 min in the absence (control) or the presence of anti-JAM-C antibody H33 [19]
and used as matrix for the e-EPC adhesion. e-EPCs were stained with Cell Tracker Green-CMFDA
(5-chloromethylfluorescein diacetate) (Molecular Probes, Eugene, Oregon) and after detachment with
trypsin were resuspended in RPMI containing 0.5 % BSA. A total of 2 × 104 e-EPCs/well, in the absence
(control) or presence of anti-JAM-C antibody H33 (30 µg/mL) were added to the HUVEC monolayer
and allowed to adhere for 20 min at 37 ◦C in 5% CO2. Total fluorescence and retained cell fluorescence
were measured in triplicate before and after washing with warm RPMI using a fluorescent plate reader
(Titertek Multiscan, Labsystems) at 485 nm excitation and 520 nm emission. HUVEC monolayers in
the RPMI medium without fluorescent e-EPCs were used as negative controls. Adherent e-EPCs were
quantified as previously described [47].
4.7. Invasion Assay
An invasion assay was performed using BD BioCoatTM MatrigelTM Invasion Chambers
(inserts and companion 24-well plates, 8-µm pore size; BD Bioscience). Inserts stored at -20 ◦C,
were first allowed to come to room temperature. To rehydrate the matrigel, warm MAM was added to
the interior of the inserts and bottom wells (500 µL/insert and bottom chamber) and the plates were
incubated for 2 h at 37 ◦C. The cells were harvested, and cell suspensions of 2 × 105 cells/mL were
prepared in MAM. After removing the medium used for the rehydration of the matrigel, 500 µL of cell
suspension was placed in each insert and 750 µL of MAM (control) or of tumor conditioned medium
(TCM) was placed in the bottom chambers of the transwell system. The plates were incubated for 24 h
at 37 ◦C in 5% CO2. The cells that did not invade were removed from the inserts using cotton swabs.
Cells that invaded and attached to the underside of the filter were stained with Diff-Quik staining-kit
(Allegiance), which contained a fixative and two staining solutions. Each insert was sequentially
transferred in each solution and two beakers of water, then allowed to air dry. Once dried, the filters
were removed from each insert and placed bottom-side down on a drop of immersion oil on a slide. A
second, very small drop of oil was placed on the filter and a glass cover slip was placed on top of that.
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4.8. In Vitro Transendothelial Migration assay
Transendothelial migration assays were performed in transwells of 6.5 mm filters and 8 µm pores
(Corning, Costar, Amsterdam, The Netherlands). Inserts were coated with 10 µg/mL fibronectin from
human plasma (Sigma-Aldrich, Steinheim, Germany). HUVECs were seeded on the transwell filters
and grown without medium in the lower compartments for 48 h in a humidified atmosphere (37 ◦C and
5% CO2). In parallel wells, before the assay, the confluence of the HUVEC monolayers was verified by
staining with 0.1% crystal violet for 30 min followed by two washes with PBS 1×. The monolayers were
observed using an inverted microscope. At the beginning of the experiment, 600 µL of migration assay
medium (MAM) (serum-free DMEM with 0.5% BSA, 25 mM HEPES, 1× penicillin/streptomycin, and 2
mM L-glutamine) or 600 µL of tumor-conditioned medium (TCM) was added to the lower compartment
of the transwell plate. Where indicated, HUVEC monolayers and e-EPCs were preincubated (at 37
◦C, 5% CO2) for 20–30 min with 30 µg/mL H33 (anti-JAM-C). In a final volume of 100 µL of MAM, 1
× 105 e-EPCs were added to the upper chambers. To normalize the migration of the progenitor cells
to the migration of the endothelial cells in the monolayer, the same experiment was run in parallel
without e-EPCs but with MAM in the upper chambers. The experiment was terminated after 20–22
h. Nonmigrated cells were removed from the upper surface using cotton swabs. Cells that migrated
to the underside of the filter were fixed in cold methanol for 5 min, washed in ddH2O and the filter
was mounted on a glass slide with Mowiol-DAPI. Each experiment was performed in triplicate and
the cells were counted on a fluorescent microscope (Axioplan 2 imaging, Zeiss, Jena, Germany) in six
fields on one diagonal of each filter.
4.9. In Vitro Tube Formation Assay
MatrigelTM (BD Biosciences, Heidelberg, Germany) was added to the wells of a 96-well plate
in a volume of 50 µL and allowed to solidify at 37 ◦C for 30 min. Cells (e-EPDCs: 10 × 104/mL or
HUVECs 17 × 104 cells/mL) were added to each well in 100 µL of Endothelial Cell Growth Medium plus
supplements. Untransfected cells, control siRNA and JAM-C siRNA cells were used 72 h after siRNA
transfection. Where indicated, cells were preincubated with 20 µg/mL r-mouse and r-human JAM-C
respectively (R&D Systems) and 60 µg/mL of anti-JAM-C antibody (H33) for 20 min at 37 ◦C. Cells
were then incubated at 37 ◦C in 5% CO2 for 24 h and images were obtained at intervals. Endothelial
cord-like structures were quantified using ImageJ software by determining the total tube length from
four representative 100× images/well/mm2 for HUVECs and the total area of cord structure from four
representative 100× or 200× images/well/mm2 for e-EPDCs.
4.10. Animals
C57BL/6 female mice were used at 12 weeks of age. Experiments were performed in accordance
with the approved institutional protocol and the guidelines of the Institutional Animal Care and Use
Committee and in conformity with the German Law for Animal Protection and the National Institute
of Health Guidelines for Care and Use of Laboratory Animals (Regierungsprasidium Karlsruhe, AZ:
35-9185.81/G-105/04, Karlsruhe, Germany).
4.11. LLC1 Tumor in the Dorsal Skin-Fold Chamber Model
We established a syngeneic tumor model by implanting 1 × 106 of highly angiogenic murine
Lewis lung carcinoma cells into dorsal skin-fold chambers in C57BL/6 mice (n = 3). This transparent
chamber model [48] allowed for direct and noninvasive assessment of the tumor microcirculation using
intravital microscopy [49]. The tumor mass was identified as previously described [8,50]. Once the
tumors established their microvascular system and initiated tumor growth (50 mm3), which was by
day 17 post-implantation, intravital video-microscopy was used to characterize the tumor vessels by
visualizing previous intravenous (IV) injection of fluorescein isothiocyanate (FITC)-Dextran 150,000.
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Tumors were also explanted from the skin-fold chambers and analyzed for JAM-C expression by
immunofluorescence (n = 3).
4.12. Intravital Fluorescence Videomicroscopy
Intravital multi-fluorescence video-microscopy was performed as previously described [8,49].
On the day of experiment, a polyethylene catheter (PE-10) was inserted into the right common
carotid artery for systemic administration of FITC-Dextran and injection of the antibodies or PBS and the
e-EPCs [49]. To study the role of JAM-C in the recruitment process of e-EPCs to the tumor endothelium,
20 min prior to e-EPC injection, mice were injected with 100 µg of anti-JAM-C antibody (H33) in 150 µL
of PBS 1× (n = 4), or 100 µg of anti-human CD44 (9B5, used as irrelevant antibody, rat IgG2a) in 150 µL
of PBS 1× (n = 2) or 150 µL of PBS 1× (n = 5). After visualization of the tumor microvasculature, 3 x 105
DiI-labeled e-EPCs resuspended in 600 µL of physiological saline solution were infused in three 200 µL
aliquots (3 injections/animal). This protocol allowed the dynamic interaction between the e-EPCs and
the tumor endothelium to be assessed within three different microvascular regions (size: 1.2 mm2).
During the intra-arterial cell injection, the absolute number of e-EPCs that passed through (100% input)
and the number of EPCs which were arrested and adhered to the microvasculature (3 or 4 regions
of interest/animal/group) were determined. Adherent e-EPCs were classified as cells that remained
attached to the vessel wall for more than 2 s, despite an unaltered microvascular blood flow. To exclude
recirculating cells from the analysis, the observation period after cell injection was limited to 20 s
and an interval of 3 min was allowed before the next cell infusion [51]. The tumor microvasculature
was scanned at 5 min, 1 h and 2 days after cell injection to assess permanent e-EPC–endothelium
interactions. The mice were intraperitoneally injected with the same amount of PBS 1×, isotype control
antibody or anti-mouse JAM-C for the following two days after cell infusion.
4.13. Statistical Analysis
Bar graphs represent the mean ± SD. All experiments were evaluated using two-tailed Student’s
t-test or 2-way AVOVA. p < 0.05 was considered statistically significant. The symbol * indicated a value
of p < 0.05, ** p < 0.01, *** p < 0.001.
Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/21/4/1209/s1.
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